AVO.L - Advanced Oncotherapy plc

LSE - LSE Delayed Price. Currency in GBp

Advanced Oncotherapy plc

4 Tenterden Street
Third Floor
London W1S 1TE
United Kingdom
44 20 3617 8728

IndustryMedical Devices
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael Jeffrey SinclairExec. Chairman1.18MN/A1943
Mr. Nicolas SerandourCEO & Exec. Director1.21MN/AN/A
Prof. Stephen MyersExec. Director416.28kN/A1947
Mr. Ed LeeCOO & Pres of EuropeN/AN/AN/A
Mr. Graham PugheSr. Vice-Pres of Accounting & ITN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Advanced Oncotherapy plc, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Corporate Governance

Advanced Oncotherapy plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.